LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION April 22, 2025 TO: Honorable Jay Dean, Chair, House Committee on Insurance FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: HB3057 by Landgraf (Relating to network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy.), As Introduced Estimated Two-year Net Impact to General Revenue Related Funds for HB3057, As Introduced: an impact of $0 through the biennium ending August 31, 2027. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill. General Revenue-Related Funds, Five- Year Impact: Fiscal Year Probable Net Positive/(Negative) Impact toGeneral Revenue Related Funds2026$02027$02028$02029$02030$0All Funds, Five-Year Impact: Fiscal Year Probable Savings/(Cost) fromRETIRED SCHOOL EMP GROUP INSURANCE989 Probable (Cost) fromSchool Employees UGIP Trust Fund8552026($3,415,467)$02027($3,644,303)($3,374,592)2028($3,888,472)($3,509,576)2029($4,148,999)($3,649,959)2030($4,426,982)($3,795,957) Fiscal AnalysisThe bill would expand access to Chimeric Antigen Receptor T-Cell (CAR T) therapy. Health benefit plans that cover CAR T therapy would be required to allow CAR T to be provided at any treatment center that qualifies as a certified healthcare facility in accordance with Food and Drug Administration standards.The bill would take effect on September 1, 2025, and apply to health care plans issued or renewed on or after January 1, 2026.
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION
April 22, 2025
TO: Honorable Jay Dean, Chair, House Committee on Insurance FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: HB3057 by Landgraf (Relating to network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy.), As Introduced
TO: Honorable Jay Dean, Chair, House Committee on Insurance
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: HB3057 by Landgraf (Relating to network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy.), As Introduced
Honorable Jay Dean, Chair, House Committee on Insurance
Honorable Jay Dean, Chair, House Committee on Insurance
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
HB3057 by Landgraf (Relating to network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy.), As Introduced
HB3057 by Landgraf (Relating to network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy.), As Introduced
Estimated Two-year Net Impact to General Revenue Related Funds for HB3057, As Introduced: an impact of $0 through the biennium ending August 31, 2027. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
Estimated Two-year Net Impact to General Revenue Related Funds for HB3057, As Introduced: an impact of $0 through the biennium ending August 31, 2027. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
General Revenue-Related Funds, Five- Year Impact:
2026 $0
2027 $0
2028 $0
2029 $0
2030 $0
All Funds, Five-Year Impact:
2026 ($3,415,467) $0
2027 ($3,644,303) ($3,374,592)
2028 ($3,888,472) ($3,509,576)
2029 ($4,148,999) ($3,649,959)
2030 ($4,426,982) ($3,795,957)
Fiscal Analysis
The bill would expand access to Chimeric Antigen Receptor T-Cell (CAR T) therapy. Health benefit plans that cover CAR T therapy would be required to allow CAR T to be provided at any treatment center that qualifies as a certified healthcare facility in accordance with Food and Drug Administration standards.The bill would take effect on September 1, 2025, and apply to health care plans issued or renewed on or after January 1, 2026.
Methodology
The Teacher Retirement System (TRS) indicates that the cost to TRS-Care, the retired school employee group insurance program, would be $3.4 million in fiscal year 2026, $3.6 million in fiscal year 2027, increasing to $4.4 million in fiscal year 2030. TRS estimates the cost to TRS-ActiveCare, the school employees uniform group insurance program, would be $3.4 million beginning in fiscal year 2027, increasing to $3.8 million in fiscal year 2030. Estimated annual cost increases are based on current medical trends. According to the Health and Human Services Commission (HHSC), Medicaid managed care organizations (MCOs) are required to provide access to all medically necessary Medicaid covered services through an adequate provider network. MCOs are also responsible for negotiating contracts with providers for all covered services. HHSC has not indicated an expected cost to implement the provisions of the bill.Other state agencies and institutions of higher education are already in compliance with the provisions of the bill, and their costs could be absorbed using existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
LBB Staff: b > td > JMc, AAL, ASA, ENA
JMc, AAL, ASA, ENA